Three Doses of OPC-34712 or Placebo for Acute Schizophrenia
About this title
Read the official source — NCT01396421Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 59 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 636
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Japan, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01396421
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock, United States · Garden Grove, United States · Glendale, United States
46 more locations
- Oakland, United States
- Oceanside, United States
- San Diego, United States
- Bradenton, United States
- Miami Springs, United States
- Orlando, United States
- Fresh Meadows, United States
- Jamaica, United States
- Dayton, United States
- Charleston, United States
- Austin, United States
- Kirkland, United States
- Burlington, Canada
- Chatham, Canada
- Fujisawa-shi, Japan
- Kunigami-gun, Japan
- Sakai-shi, Japan
- Setagaya-ku, Japan
- Kumamoto, Japan
- Daugavpils, Latvia
- Jelgava, Latvia
- Liepāja, Latvia
- Riga, Latvia
- Strenči, Latvia
- Choroszcz, Poland
- Gdansk, Poland
- Lodz, Poland
- Arad, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Focşani, Romania
- Piteşti, Romania
- Targoviste, Romania
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Sad, Serbia
- Incheon, South Korea
- Seoul, South Korea
- Chernihiv, Ukraine
- Dnipropetrovsk, Ukraine
- Hlevakha, Ukraine
- Kherson, Vil. Stepanivka, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Simferopol, Ukraine
- Vinnytsia, Ukraine
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
